Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eng Huat Tan

Showing results (81-90 of 108) with videos related to

Pageof 11
Sort By:
Nature Medicine|September 19, 2017
Long noncoding RNA EGFR-AS1 mediates epidermal growth factor receptor addiction and modulates treatment response in squamous cell carcinomaDaniel S W Tan, Fui Teen Chong, Hui Sun Leong, et al.
The Lancet. Oncology|April 17, 2016
Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trialKeunchil Park, Eng-Huat Tan, Ken O'Byrne, et al.
The Lancet. Oncology|November 11, 2018
Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 studyBenjamin J Solomon, Benjamin Besse, Todd M Bauer, et al.
International Journal of Radiation Oncology, Biology, Physics|August 15, 2006
Preliminary results of a randomized study (NPC-9902 Trial) on therapeutic gain by concurrent chemotherapy and/or accelerated fractionation for locally advanced nasopharyngeal carcinomaAnne W M Lee, Stewart Y Tung, Anthony T C Chan, et al.
Nature Communications|May 15, 2023
Clinical efficacy and biomarker analysis of dual PD-1/CTLA-4 blockade in recurrent/metastatic EBV-associated nasopharyngeal carcinomaDarren Wan-Teck Lim, Hsiang-Fong Kao, Lisda Suteja, et al.
JAMA Network Open|November 5, 2021
Association of Clinicopathologic and Molecular Tumor Features With Recurrence in Resected Early-Stage Epidermal Growth Factor Receptor-Positive Non-Small Cell Lung CancerStephanie P L Saw, Siqin Zhou, Jianbin Chen, et al.
Cell Metabolism|October 25, 2025
Induction of a metabolic switch from glucose to ketone metabolism programs ketogenic diet-induced therapeutic vulnerability in lung cancerZhengwei Wu, Zhenxun Wang, Seow Qi Ng, et al.
Cancer Research|April 8, 2024
Oncogene-Driven Non-Small Cell Lung Cancers in Patients with a History of Smoking Lack Smoking-Induced MutationsChen-Yang Huang, Nanhai Jiang, Meixin Shen, et al.
Cancer|February 29, 2024
Detection of circulating tumor DNA with ultradeep sequencing of plasma cell-free DNA for monitoring minimal residual disease and early detection of recurrence in early-stage lung cancerAaron C Tan, Gillianne G Y Lai, Stephanie P L Saw, et al.
European Journal of Cancer (Oxford, England : 1990)|November 27, 2022
PD-L1 score as a prognostic biomarker in asian early-stage epidermal growth factor receptor-mutated lung cancerStephanie P L Saw, Win Pin Ng, Siqin Zhou, et al.
Pageof 11

Showing results (81-90 of 108) with videos related to

Sort By:
Pageof 11
Nature Medicine|September 19, 2017
Long noncoding RNA EGFR-AS1 mediates epidermal growth factor receptor addiction and modulates treatment response in squamous cell carcinomaDaniel S W Tan, Fui Teen Chong, Hui Sun Leong, et al.
The Lancet. Oncology|April 17, 2016
Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trialKeunchil Park, Eng-Huat Tan, Ken O'Byrne, et al.
The Lancet. Oncology|November 11, 2018
Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 studyBenjamin J Solomon, Benjamin Besse, Todd M Bauer, et al.
International Journal of Radiation Oncology, Biology, Physics|August 15, 2006
Preliminary results of a randomized study (NPC-9902 Trial) on therapeutic gain by concurrent chemotherapy and/or accelerated fractionation for locally advanced nasopharyngeal carcinomaAnne W M Lee, Stewart Y Tung, Anthony T C Chan, et al.
Nature Communications|May 15, 2023
Clinical efficacy and biomarker analysis of dual PD-1/CTLA-4 blockade in recurrent/metastatic EBV-associated nasopharyngeal carcinomaDarren Wan-Teck Lim, Hsiang-Fong Kao, Lisda Suteja, et al.
JAMA Network Open|November 5, 2021
Association of Clinicopathologic and Molecular Tumor Features With Recurrence in Resected Early-Stage Epidermal Growth Factor Receptor-Positive Non-Small Cell Lung CancerStephanie P L Saw, Siqin Zhou, Jianbin Chen, et al.
Cell Metabolism|October 25, 2025
Induction of a metabolic switch from glucose to ketone metabolism programs ketogenic diet-induced therapeutic vulnerability in lung cancerZhengwei Wu, Zhenxun Wang, Seow Qi Ng, et al.
Cancer Research|April 8, 2024
Oncogene-Driven Non-Small Cell Lung Cancers in Patients with a History of Smoking Lack Smoking-Induced MutationsChen-Yang Huang, Nanhai Jiang, Meixin Shen, et al.
Cancer|February 29, 2024
Detection of circulating tumor DNA with ultradeep sequencing of plasma cell-free DNA for monitoring minimal residual disease and early detection of recurrence in early-stage lung cancerAaron C Tan, Gillianne G Y Lai, Stephanie P L Saw, et al.
European Journal of Cancer (Oxford, England : 1990)|November 27, 2022
PD-L1 score as a prognostic biomarker in asian early-stage epidermal growth factor receptor-mutated lung cancerStephanie P L Saw, Win Pin Ng, Siqin Zhou, et al.
Pageof 11